Consistently, we found that in vivo targeted delivery of the DN-TRPC6 construct into the MetS coronary artery wall using an in vivo intracoronary electroporation approach resulted in decreased histamine-induced [Ca2+]i transients in the MetS coronary artery segments. This evidence concerns the gene TRPC6 and metabolic syndrome.